A paucimorphic variant in the HMG-CoA reductase gene is associated with lipid-lowering response to statin treatment in diabetes: a GoDARTS study
- 1 December 2008
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Pharmacogenetics and Genomics
- Vol. 18 (12), 1021-1026
- https://doi.org/10.1097/fpc.0b013e3283106071
Abstract
Background Considerable interindividual variation exists in cholesterol-lowering response to 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMGCR) inhibitors (statins). HMGCR catalyzes the rate-limiting step in cholesterol biosynthesis, and also plays a significant role in cholesterol homeostasis. We evaluated the association of a single nucleotide polymorphism (rs17238540) in the HMGCR gene with lipid-lowering response to statins in a large population-based cohort of patients with diabetes. Methods One thousand six hundred and one patients commencing statins between 1993 and 2006 were identified from the Genetics of Diabetes Audit and Research in Tayside Scotland database. Statin response was determined by both percentage change in lipids, and whether patients failed to reach a total cholesterol target of less than or equal to 4 mmol/l. Covariates included HMGCR genotype, baseline lipids, age, sex, adherence and statin dose. All patients were genotyped for rs17238540 using a TAQMAN-based allelic discrimination assay. Results Twenty-eight percent of individuals homozygous for the more frequent T allele failed to reach target compared with 51% of the individuals with a single copy of the minor G allele (carrier frequency 3.3%), with an adjusted odds ratio (95% confidence interval) for failure of 2.93 (1.61–5.34) mmol/l, P=0.0005. In addition, we found that the heterozygotes had a 13% smaller reduction in total cholesterol (−32.3 vs. −37.1%, P=0.0081) and a 27% smaller reduction in triglycerides (−27.5 vs. −37.6%, P=0.0046). Conclusion Individuals heterozygous for the G allele of rs17238540 in the HMGCR gene may respond less well to statin therapy in terms of total cholesterol and triglyceride lowering.Keywords
This publication has 28 references indexed in Scilit:
- Apolipoprotein E genotypes are associated with lipid-lowering responses to statin treatment in diabetes: a Go-DARTS studyPharmacogenetics and Genomics, 2008
- Pharmacogenomics of statin responseCurrent Opinion in Lipidology, 2007
- Common Cholesteryl Ester Transfer Protein Gene Polymorphisms and the Effect of Atorvastatin Therapy in Type 2 DiabetesDiabetes Care, 2003
- Apolipoprotein E genotype affects plasma lipid response to atorvastatin in a gender specific mannerAtherosclerosis, 2001
- Apolipoprotein E genotypes and response of plasma lipids and progression–regression of coronary atherosclerosis to lipid-lowering drug therapyJournal of the American College of Cardiology, 2000
- Association of the Apolipoprotein B Gene Polymorphisms with Cholesterol Levels and Response to Fluvastatin in Brazilian Individuals with High Risk for Coronary Heart Diseasecclm, 2000
- The Role of a Common Variant of the Cholesteryl Ester Transfer Protein Gene in the Progression of Coronary AtherosclerosisThe New England Journal of Medicine, 1998
- A comparative study of the efficacy of simvastatin and gemfibrozil in combined hyperlipoproteinemia: prediction of response by baseline lipids, apo E genotype, lipoprotein(a) and insulinAtherosclerosis, 1997
- Effect of apolipoprotein E and A-IV phenotypes on the low density lipoprotein response to HMG CoA reductase inhibitor therapyAtherosclerosis, 1995
- Effect of apolipoprotein E polymorphism and Xbal polymorphism of apolipoprotein B on response to lovastatin treatment in familial and non‐familial hypercholesterolaemiaJournal of Internal Medicine, 1991